Anticoagulation Strategies for Giant and Expanding Coronary Aneurysms in Kawasaki Disease

Primary Indications for Systemic Anticoagulation

• Patients with coronary artery aneurysms ≥ 8 mm in absolute diameter or Z‑score ≥ 10 require dual therapy with low‑dose aspirin (3–5 mg/kg/day) plus systemic anticoagulation (warfarin or LMWH). American Heart Association guideline. 1, 2
• Systemic anticoagulation is also recommended for rapidly expanding aneurysms approaching a Z‑score ≥ 10, even before the absolute size threshold is reached. American Heart Association guideline. 1, 3

Choice of Anticoagulant Agent

• Warfarin: target INR 2.0–3.0; initial dose 0.1 mg/kg/day orally; requires frequent INR monitoring (daily until stable, then at least monthly). American Heart Association guideline. 4, 5, 6
• Low‑Molecular‑Weight Heparin (LMWH, Enoxaparin): target anti‑factor Xa 0.5–1.0 U/mL (checked 4–6 h after dose). Preferred for infants and young children, especially during the acute phase when aneurysms are still expanding. American Heart Association guideline. 1, 6, 3
• Dosing of LMWH:
   < 2 months of age – 1.5 mg/kg SC every 12 h
   ≥ 2 months of age – 1.0 mg/kg SC every 12 h
   Target anti‑Xa 0.5–1.0 U/mL (checked 4–6 h post‑dose)
  *American Heart Association** guideline. 6

Transition Between Agents

• Transition from LMWH to warfarin may be considered once aneurysms have stopped expanding and the patient is clinically stable. American Heart Association guideline. 1, 6, 3

Triple‑Therapy Considerations (High‑Risk Scenarios)

• Triple therapy (aspirin + second antiplatelet + anticoagulation) may be employed for patients with exceptionally high thrombotic risk, such as giant aneurysms with recent coronary thrombosis or recent thrombolysis. American Heart Association guideline. 1, 6, 3
• The second antiplatelet agent is typically clopidogrel (1 mg/kg/day, max 75 mg/day). American Heart Association guideline. 4, 5
• Triple therapy carries a greater bleeding risk and must be balanced against thrombotic risk on an individual basis. American Heart Association guideline. 6, 3

Management of Patients Without Coronary Involvement

• Children without coronary artery changes receive low‑dose aspirin until 4–6 weeks after illness onset, then discontinue. American Heart Association guideline. 1, 3

Hemodynamic Pathophysiology of Giant Aneurysms

• Giant aneurysms create markedly abnormal flow (low wall shear stress, stasis, turbulence) that promotes thrombus formation via platelet activation and endothelial dysfunction. American Heart Association guideline. 4, 5, 2

Antithrombin Deficiency and LMWH Effectiveness

• > 50 % of Kawasaki disease patients develop transient antithrombin deficiency during the acute phase, which can reduce LMWH efficacy. American Heart Association guideline. 1, 6, 3
• If target anti‑Xa levels are not achieved on appropriate LMWH dosing, measure antithrombin levels. American Heart Association guideline. 1, 6, 3
• When antithrombin deficiency is confirmed, administer fresh‑frozen plasma or antithrombin supplementation. American Heart Association guideline. 1, 6

Drug‑Interaction Precautions

• Ibuprofen and other NSAIDs that inhibit cyclo‑oxygenase should be avoided in patients receiving aspirin for antiplatelet effect. American Heart Association guideline. 1, 3

Acute Coronary Thrombosis Management

• Immediate thrombolytic therapy or mechanical intervention is required for acute coronary thrombosis with actual or impending occlusion. American Heart Association guideline. 1, 2, 3
• tPA (tissue plasminogen activator) is the most commonly used thrombolytic: 0.5 mg/kg/hour IV over 6 hours. American Heart Association guideline. 1, 6, 3
• Mechanical restoration of coronary blood flow via cardiac catheterization may be performed in patients of sufficient size. American Heart Association guideline. 1, 3

Management of Coronary Artery Aneurysms in Kawasaki Disease

Risk Stratification and Treatment Selection

• The American Heart Association recommends that the size of the aneurysm determines the intensity of treatment and prognosis, with small aneurysms (Z-score ≥2.5 to <5) requiring low-dose aspirin 3-5 mg/kg/day 7
• The American College of Cardiology recommends that medium aneurysms (Z-score ≥5 to <10, absolute diameter <8 mm) require dual antiplatelet therapy with aspirin plus clopidogrel 8, 7
• The American Heart Association recommends that giant aneurysms (≥8 mm or Z-score ≥10) require combined therapy with aspirin plus warfarin (INR 2.0-3.0) 8, 9, 7

Critical Period of Observation

• The highest risk of thrombosis occurs in the first 3 months of illness, with a peak between 15-45 days 10, 8
• The American Academy of Pediatrics recommends that patients with giant aneurysms undergo echocardiography at least twice a week during rapid coronary artery expansion 10, 8
• Echocardiography should be performed at least once a week for the first 45 days, and then monthly until 3 months 10
• The American Heart Association recommends that echocardiography be performed every 3 months until the end of the first year 10

Treatment of Acute Coronary Thrombosis

• The American College of Cardiology recommends that thrombolytic therapy (class I recommendation) be performed with intravenous tPA plus oral aspirin plus intravenous heparin 10, 11
• The American Heart Association recommends that fibrinogen be maintained >100 mg/dl to minimize bleeding 10
• Coagulation should be monitored at least daily 10

Important Clinical Nuances

• The pathophysiology of thrombosis in Kawasaki disease differs from atherosclerotic disease in adults, with larger thrombus size and lower blood flow rates creating prothrombotic conditions 10, 7
• Triple therapy may be considered for infants with extraordinary risk of thrombosis (giant aneurysms + recent thrombosis history): aspirin + second antiplatelet + anticoagulant (warfarin or low-molecular-weight heparin) 8, 9

Long-term Prognosis

• Approximately half of coronary aneurysms regress within 1-2 years, especially smaller and fusiform aneurysms 12, 13
• The risk of myocardial infarction from coronary thrombosis is highest in the first 2 years after disease onset 12, 13

Critical Errors to Avoid

• Inadequate intensification of antithrombotic therapy in rapidly expanding aneurysms 7
• Discontinuation of aspirin during influenza or chickenpox infections without replacement with clopidogrel or low-molecular-weight heparin (risk of Reye's syndrome) 8, 9
• Underestimation of asymptomatic myocardial infarction in infants and young children 10, 8